• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • Cardiology, Diabetes & Nephrology – USA
    • Hatter Horizon Series
    • The 18th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2021
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2021
    • Multiple Sclerosis Nurses at the Limits 2021
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

CDNATL 2015: Event now closed

CDNATL3-Logo-photoshop

The CDNATL 2015 event is now closed


The multimedia archive of the event can be viewed by clicking here.

Cardiology, Diabetes & Nephrology at the Limits Brazil
Thursday 21 & Friday, 22 October 2021, Virtual Meeting

Hatter Horizon GP Meeting
Monday, 1 November 2021
London, UK

Hatter Horizon Series
Monday, 22 November 2021, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2022
Monday, 4 & Tuesday, 5 April 2022, London,UK

Cell Therapy at the Limits 2022
June 2022, London, UK

The 19th Malvern Diabetic Foot Conference
Wednesday, 11 - Friday, 13 May 2022, Malvern, UK

Multiple Sclerosis Nurses
at the Limits
Friday, 16 & Saturday, 17 September 2022, London, UK

Multiple Sclerosis at the Limits
Tuesday, 27 & Wednesday, 28 September 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits Japan
Saturday 15th & Sunday 16th October 2022, Tokyo, Japan

Cardiology, Diabetes & Nephrology at the Limits Canada
Q3 2022, Toronto, Canada

Pages

  • DJ test
  • MSTV
  • Homepage
    • /cdnatl2021
    • Announcements
    • CDNATL2019
    • Corporate Hospitality
    • Professor Lionel Opie – Obituary from The Lancet
    • Chairs
    • The ATL Series
    • The Lancet Editorial
    • Core Principles – Education for Africa
    • Independence
    • Academic Founders
  • Oncology
    • OATL 2016
      • OATL 2016: CME Accreditation
      • OATL 2016: Conflict of Interest forms
      • OATL 2016: Delegate Feedback
      • OATL 2016: Chairpersons
      • OATL 2016: Dr Richard Horton Video
      • OATL 2016: Self Funded Registration
      • OATL 2016: Venue
      • OATL 2016: Introduction
      • The Lancet Oncology/Haematology – Fully Funded Places Offer
      • OATL 2016: Schedule
      • OATL 2016: Programme
      • OATL 2016: Information
      • OATL 2016: Hotel
    • Oncology at the Limits: Delegate feedback 2009 to 2014
    • OATL 2017
      • OATL 2017: CME Accreditation
      • OATL 2017: Conflict of Interest forms
      • OATL 2017: Delegate Feedback
      • OATL 2017: Registration
      • OATL 2017: Chairs
      • OATL 2017: Venue
      • OATL 2017: Introduction
      • OATL 2017: Schedule
      • OATL 2017: Programme
      • OATL 2017: Information
      • OATL 2017: Hotel
    • OATL 2018: Introduction
    • OATLC 2018: Introduction
    • OATL Event Closed
      • OATL 2014: Event now closed
      • OATL 2015: Event now closed
        • OATL 2015: Affiliate Feedback
      • OATL 2012: Event now closed
      • OATL 2011: Event now closed
      • OATL 2010: Event now closed
  • Delegate Invitations
  • Disclosure
  • Sprint 1 Registration
  • UKONS / Gilead Symposium Presentations
  • General Data Protection Regulations – Opt In
  • General Data Protection Regulations Contact
  • Multiple Sclerosis
    • MSATL 2017: Introduction
      • MSATL 2017: CME Accreditation
      • MSATL 2017: Conflict of Interest Forms
      • MSATL 2017: Day Delegate Registration
      • MSATL 2017: Delegate Registration
      • MSATL 2017: European Delegate Registration
      • MSATL 2017: European Delegate Reimbursement
      • MSATL 2017: Faculty Registration
      • MSATL 2017: Faculty Registration
      • MSATL 2017: Staff Registration
      • MSATL 2017: Student Registration
      • Multiple Sclerosis at the Limits 2017
      • Reimbursement
      • Reimbursement
      • MSATL 2017: Chairs
      • MSATL 2017: Venue
      • MSATL 2017: Schedule
      • MSATL 2017: Programme
      • MSATL 2017: Supporters
      • MSATL 2017: Hotel
      • MSATL 2017: Information
    • MSATL 2018: Introduction
      • MSATL 2018: Pre-register
      • MSATL 2018: CME Accreditation
      • MSATL 2018: Conflict of Interest Forms
      • MSATL 2018: Delegate Registration
      • MSATL 2018: Delegate Registration
      • MSATL 2018: Delegate Registration
      • MSATL 2018: Delegate Registration
      • MSATL 2018: EUR Reimbursement
      • MSATL 2018: Faculty Registration
      • MSATL 2018: Faculty Registration
      • MSATL 2018: GBP Reimbursement
      • MSATL 2018: Nominate Colleagues
      • MSATL 2018: Nominate Nurses for MSNATL 2019
      • MSATL 2018: Registration
      • MSATL 2018: Staff Registration
      • MSATL 2018: Student Registration
      • MSATL 2018: Chairs
      • MSATL 2018: Venue
      • MSATL 2018: Schedule
      • MSATL 2018: Programme
      • MSATL 2018: Supporters
      • MSATL 2018: Hotel
      • MSATL 2018: Information
    • MSATL 2020: Introduction
      • MSATL 2020: Faculty Registration
      • MSATL 2020: Faculty Registration
    • MSNATL 2019: Introduction
      • MSNATL 2019: Express Interest
      • MSNATL 2019: Conflict of Interest Forms
      • MSNATL 2019: Nominate Colleagues
      • MSNATL 2019: Delegate Registration
      • MSNATL 2019: Delegate Registration
      • MSNATL 2019: Delegate Registration
      • MSNATL 2019: EUR Reimbursement
      • MSNATL 2019: Faculty Registration
      • MSNATL 2019: Faculty Registration
      • MSNATL 2019: GBP Reimbursement
      • MSNATL 2019: Registration
      • MSNATL 2019: Staff Registration
      • MSNATL 2019: Student Registration
      • MSNATL 2019: Chairs
      • MSNATL 2019: Venue
      • MSNATL 2019: Programme
      • MSNATL 2019: Supporters
      • MSNATL 2019: Schedule
      • MSNATL 2019: Hotel
      • MSNATL 2019: Information
    • MSNATL 2020: Introduction
      • MSNATL 2020: Faculty Registration
      • MSNATL 2020: Faculty Registration
    • MSNATL 2019: Information
  • CDN2018
  • The Lancet – Fully funded places offer
  • Accelerating Cancer Immunotherapy
    • ACI Programme
    • ACI Chairs
    • Pre-Register – ACI Europe 2020
    • Sponsor Registration
    • Sponsor Registration
    • ACI 2017 Venue
    • ACI 2017: Supporters
  • Multimedia
    • Cardiology, Diabetes & Nephrology at the Limits 2017: Multimedia
      • Debate – (For: Professor Iain Macdougall – Against: Dr Marc Pfeffer): Strategies for optimising haemoglobin in CKD (both pre and post dialysis) & CV Disease. What level and how to get there?
      • Dr C Noel Bairey Merz: Is it time to look at microvascular angina? Are these the new limits?
      • Dr Chris Winearls: eGFR & CKD Staging. Better understanding or a struggle with the law of unintended consequences?
      • Dr Daniel Lenihan: Cardio-Oncology – preventing the cancer patient of today being the heart failure patient of tomorrow!
      • Dr Peter Libby: Novel concepts of the pathogenesis of the acute coronary syndromes.
      • Dr Steven Weisbord: rials and tribulations in AKI. Do we know where we are going?
      • Professor Allison Goldfine: GLP-1 analogues & DPPIV Inhibitors – are there new limits for beneficial cardiovascular outcome in type 2 diabetes?
      • Professor Bernard Gersh: PCI vs CABG for multi-vessel and left main coronary disease – do we have the evidence?
      • Professor David Wheeler: Diabetes & the kidney: BP control-how low can you go?
      • Professor Gerd Heusch: The preconditioning phenomenon – lost in translation?
      • Professor John Wilding: SGLT2 inhibition – a novel strategy to improve type 2 diabetes, cardiovascular & renal outcome
      • Professor Kausik Ray: PCSK9 inhibition – have we reached the limits of lipid lowering and outcome?
      • Professor Liesl Zühlke: The prevention, management and control of rheumatic heart disease: are we at the limits?
      • Professor Naomi Levitt: The global burden of diabetes.
      • Professor Natan Bornstein: What is the connection between the heart and the brain?
      • xxx: yyy
    • Cardiology, Diabetes & Nephrology at the Limits 2018: Multimedia
    • Cardiology, Diabetes & Nephrology at the Limits 2019: Multimedia
    • CDNATL 2019: Vifor Symposium
    • Hatter Horizon Series 2017
      • The global burden of diabetes – Professor Paul Zimmet
    • Hatter Horizon Series 2018: Multimedia
    • Multiple Sclerosis at the Limits 2018: Multimedia
    • Multiple Sclerosis Nurses at the Limits 2019: Multimedia
    • Accelerating Cancer Immunotherapy 2017: Multimedia
      • Dr Alena Gros Vidal: Targeting the cancer mutanome
      • Dr Christian Blank: Emerging approaches in melanoma immunotherapy
      • Dr James Larkin: Ongoing development of checkpoint trials
      • Dr James P. Allison: Immune checkpoint in cancer therapy: New insights into mechanism
      • Dr Jerome Galon: The tumor microenvironment and the dynamics of the immune response in human tumors
      • Dr Padmanee Sharma: From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy
      • Dr Ramy Ibrahim: Trends & Collaborations in the IO Space
      • Dr Sergio Quezada: Deciphering immune regulation and recognition at the tumour site
      • Professor Alan Melcher: Immuno-oncolytic viruses as cancer therapies
      • Professor Alexander MM Eggermont: Immune biomarkers and measuring response
      • Professor Crystal Mackall: Immune-based therapies for childhood cancer
      • Professor Richard Sullivan: The affordability of the extraordinary
      • Professor Robert Schreiber: Eradicating tumors using the immune system
      • Professor Tim Illidge: Radiation treatment and immunotherapy combinations to improve outcome for cancer patients
    • Oncology at the Limits 2017: Multimedia
      • Dr David Meek: How p53 can contribute to protecting cells from DNA damage
      • Dr Roy Herbst: Personalized immunotherapy for advanced non-small cell lung cancer
      • Dr Silvia von Karstedt: The biology of the TRAIL system in cancer and the associated discovery of combination therapies
      • Dr W. Mark Saltzman: Using nanoparticles for drug delivery
      • Professor Charles Swanton: Sequencing cancer genomes and personalising cancer treatments
      • Professor Christian Rolfo: Cancer and the microbiome: potential applications as a new tumor biomarker
      • Professor Dr Ambros Beer: Hybrid imaging and advances in nuclear medicine
      • Professor Eyal Gottlieb: How Metabolism affects cell growth in cancer
      • Professor Joann B. Sweasy: DNA repair in Cancer
      • Professor John Hartley: The development of novel cancer therapies involving DNA as a target
      • Professor Melinda L. Irwin: Examining the effect of exercise and weight loss on cancer biomarkers, treatment side effects and quality of life
      • Professor Rene Bernards: Synthetic lethal screens for rational drug combinations
      • Professor Tony Ng: State of the art in Molecular Imaging
      • Professor Uwe Oelfke: The next generation of radiotherapy treatment
    • Cardiology, Diabetes and Nephrology at the Limits 2016: Multimedia
      • Dr Dariush Mozaffarian: A global perspective in preventing cardiovascular disease from discovery to policy
      • Dr Joseph Bonventre: How might we be preventing acute kidney injury in 2025?
      • Dr Julian Gillmore: Amyloid- a cardiorenal disease
      • Dr Laura Mauri: Debate: Dual anti-platelet therapy post drug eluting stents – what should the limits be? Long term effects
      • Dr Rick Johnson: Fructose, urate, life and death
      • Dr Stephen Wiviott: Sodium-glucose co-transporter inhibitors, incretins, glitazones – a cardiologist’s perspective on choice and limitations
      • Prof. Dr. med. Thomas F. Lüscher: Debate: Dual anti-platelet therapy post drug eluting stents – what should the limits be? Short term effects
      • Professor Bernard Gersh: The Epidemic of Atrial Fibrillation: Is it a vascular disease?
      • Professor Jim Mann: Obesity, coronary heart disease and diabetes; Lipids vs Carbohydrates at the limits
      • Professor John Chapman: PCSK9 inhibitors-a new approach to cholesterol homeostasis – are we approaching the limits?
      • Professor John Deanfield: Preventative cardiology in youth – what are the limits?
      • Professor John McMurray: Heart failure therapy – extending the limits!
      • Professor Rajiv Agarwal: Treating the kidney protecting the heart-what are the limits?
      • Professor Valentin Fuster: The PolyPill – a new therapeutic approach
    • Oncology at the Limits 2016: Multimedia
      • Dr Daniel P. Petrylak: Immunotherapy in bladder cancer: research at the limits
      • Dr Jeff Geschwind: Image guided therapy of Hepatomas
      • Dr Mario Sznol: Cancer immunotherapy affecting patients with unresectable stage III or stage IV malignant melanoma
      • Dr Mark Lemmon: Extracting clues for developing new EGFR inhibitory approaches in cancer
      • Dr Rita Nanda: Immunotherapy for the treatment of triple-negative breast cancer
      • Prof. Dr. med. Stephanie E. Combs: High-precision radiotherapy and the integration of modern imaging techniques
      • Professor Ajay Vora: Childhood ALL in the UK: Treatment at the Limits
      • Professor Alan Ashworth: Using functional genomics to identify genes that modify the tumor cell response to therapy
      • Professor Alison Lloyd: The cellular complexity of nerve regeneration- implications for nerve repair and tumourigenesis
      • Professor Andrew Biankin: Novel Personalised Therapeutic Strategies in Pancreatic Cancer
      • Professor Bart Vanhaesebroeck: Isoforms of PI 3-kinase in cancer
      • Professor Fabrice Andre: Targeted therapy in Breast Cancer matched to individuals’ genomic alterations
      • Professor Rebecca Fitzgerald: Early detection and treatment of cancer of the oesophagus
      • Professor Robert Hawkins: T-cell mediated immunotherapies for Cancer
      • Professor Roger Stupp: Alternating electric fields and other advances for treatment of glioma
      • Professor Ruth Plummer: Phase 1 trial design
  • Support & Sponsorship
  • Secure Connection Issues, potential fix
  • Feedback
    • CDNATL 2018: Feedback
    • CDNATL 2019: Feedback
    • FOC 2019: Feedback
    • FOW 2017: Feedback
    • Gilead – Cardiff 2018: Feedback
    • Gilead – Glasgow 2018: Feedback
    • Gilead – Ireland 2018: Feedback
    • Gilead – London 2018: Feedback
    • Gilead – Oxford 2018: Feedback
    • HGP 2019: Feedback
    • HHS 2017: Feedback
    • HHS 2018: Feedback
    • MDFC 2018: Feedback
    • MSATL 2017: Feedback
    • MSATL 2018: Feedback
    • MSNATL 2019: Feedback
  • 1st British Symposium on Diabetic Neuropathy
  • Accept Invite
  • Data Protection
  • Decline Invite
  • Historic Multimedia
  • Medical Disclaimer
  • Biographies
  • Register Interest
  • Roche Feedback
  • Supporters: 2017
  • Supporters: 2016
  • Supporters
  • Supporters: 2018
  • Contact
  • Cookie Policy
  • Privacy Policy
  • Earnings Disclaimer
  • E-mail Policy
  • External Links Policy
  • Dmca Notice
  • Disclaimer
  • Anti-spam Policy
  • Terms of use
  • CDNATL 2015: Event now closed
  • CDATL 2014: Event now closed
  • CDATL 2013: Event now closed
  • CDATL 2012: Event now closed
  • CDATL 2011: Event now closed
  • CDATL 2010: Event now closed
  • CATL 2009: Event now closed
  • CDNATL 2016: Delegate Feedback
  • CDNATL 2016: Horton Industry
  • CDNATL 2016: Academic Structure
  • CDNATL 2016: Introduction
  • CDNATL 2016: Venue
  • CDNATL 2016: Programme
  • CDNATL 2016: Chairpersons
  • CDNATL 2016: Hotel
  • CDNATL 2016: Information
  • CDNATL 2016: Schedule
  • CDNATL 2017: Conflict of Interest forms
  • CDNATL 2017: Directions
  • CDNATL 2017: CME Accreditation
  • CDNATL 2017: Chairs
  • CDNATL 2017: Information
  • CDNATL 2017: Programme
  • CDNATL 2017: Schedule
  • CDNATL 2017: Venue
  • CDNATL 2017: Delegate Feedback
  • CDNATL 2017: Delegate Feedback
  • CDNATL 2017: Hotel
  • CDNATL 2018: Agent Staff Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration
  • CDNATL 2018: Delegate Registration
  • CDNATL 2018: Delegate Registration
  • CDNATL 2018: Delegate Registration – AIIMS
  • CDNATL 2018: Delegate Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration – Novo Nordisk
  • CDNATL 2018: Delegate Registration – UK
  • CDNATL 2018: Faculty Registration
  • CDNATL 2018: Faculty Registration
  • CDNATL 2018: Registration – Day
  • CDNATL 2018: Reimbursement – EU
  • CDNATL 2018: Reimbursement – UK
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Staff Registration – Novo Nordisk
  • CDNATL 2018: Student Registration
  • CDNATL 2018: Symposium Registration
  • CDNATL 2018: Vifor Symposium
  • Conflict of Interest forms
  • CDNATL 2018: CME Accreditation
  • CDNATL 2018: Venue
  • CDNATL 2018: Programme
  • CDNATL 2018: Scientific Committee
  • CDNATL 2018: Hotel
  • CDNATL 2018: Information
  • CDNATL 2018: Schedule
  • CDNATL 2018: Supporters
  • CDNATL 2019: Delegate Registration
  • CDNATL 2019: Delegate Registration – NN – Europe
  • CDNATL 2019: Delegate Registration – NN – Rest of World
  • CDNATL 2019: Delegate Registration – NN – UK
  • CDNATL 2019: Delegate Registration – NN – UK Day
  • CDNATL 2019: Delegate Registration – The Lancet D&E
  • CDNATL 2019: Delegate Registration – Vifor
  • CDNATL 2019: Delegate Registration – Vifor Symposium
  • CDNATL 2019: Faculty Registration
  • CDNATL 2019: Faculty Registration
  • CDNATL 2019: Programme
  • CDNATL 2019: Reimbursement
  • CDNATL 2019: Staff Registration
  • CDNATL 2019: Staff Registration – Napp
  • CDNATL 2019: Staff Registration – NN
  • CDNATL 2019: Staff Registration – NN
  • CDNATL 2019: Staff Registration – Vifor
  • CDNATL 2019: Student Registration
  • CDNATL 2019: Schedule
  • CDNATL 2019: Venue
  • CDNATL 2019: Hotel
  • CDNATL 2019: Scientific Committee
  • CDNATL 2019: Supporters
  • CDNATL 2019: CME Accreditation
  • CDNATL 2019: Conflict of Interest Forms
  • CDNATL 2019: Information
  • CDNATL 2020: Affiliate Registration – Novo Nordisk
  • CDNATL 2020: Delegate Registration
  • CDNATL 2020: Delegate Registration – Novo Nordisk
  • CDNATL 2020: Delegate Registration – Novo Nordisk
  • CDNATL 2020: Delegate Registration – Novo Nordisk
  • CDNATL 2020: Delegate Registration – Novo Nordisk
  • CDNATL 2020: Faculty Registration
  • CDNATL 2020: Faculty Registration
  • CDNATL 2020: Reimbursement
  • CDNATL 2020: Staff Registration
  • CDNATL 2020: Staff Registration – Novo Nordisk
  • CDNATL 2020: Staff Registration – Novo Nordisk
  • CDNATL 2021: Programme
  • CDNATL 2021: Schedule
  • CDNATL 2021: Venue
  • CDNATL 2021: Hotel
  • CDNATL 2020: Scientific Committee
  • CDNATL 2020: CME Accreditation
  • CDNATL 2021: Express Interest
  • CDNATL 2021: Express Interest
  • CDNATL 2020: Supporters
  • CDNATL 2021: Information
  • CDNB 2019: Brazil Media
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: Delegate Registration
  • CDNB 2019: English Media
  • CDNB 2019: Faculty Registration
  • CDNB 2019: Faculty Registration
  • CDNB 2019: Media Menu
  • CDNB 2019: Programme
  • CDNB 2019: Reimbursement
  • CDNB 2019: Staff Registration
  • CDNB 2019: Student Registration
  • CDNB 2019: Unicamp Registration
  • CDNB 2019: Schedule
  • CDNB 2019: Venue
  • CDNB 2019: Conference Hotel
  • CDNB 2019: Scientific Committee
  • CDNB 2019: Express Interest
  • CDNB 2019: Supporters
  • CDNB2019: Conflict of Interest Forms
  • CDNB 2019: Information
  • CDNATL 2015
  • CDNATL 2015: Affiliate Feedback
  • CDNATL 2015: Delegate Feedback
  • CDNATL 2016
  • CDNATL 2017: Introduction
  • CDNATL 2019: Introduction
  • CDNB 2019: Introduction
  • CDNATL 2018: Introduction
  • CDNATL 2021: Introduction
  • CDNATL Event Closed
  • NATL 2012: Event now closed
  • NATL 2010: Event now closed
  • NATL 2009: Event now closed

Archives

  • March 2020
  • July 2019
  • February 2019

Categories

  • At the Limits (5)
    • Announcements (5)
    • Events (5)
      • CDNATL (5)

WordPress

  • Log in
  • WordPress
  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2021 At the Limits Ltd.
This site uses cookies More info